advanced search

Welcome: Guest

log in

0 items in basket Total: £0
$0 / €0

View Basket

Global Ophthalmic Market Analysis & Forecasts to 2012

Publication Date April 2007
Publisher Visiongain
Product Type Report
Pages 180
ISBN Number not applicable
Product Code VIS00047
Price

£1,499.00
approximately: $2,292 | €1,672

OTHER ($2,292 | €1,672)Buy Now
Order above formats by FAXOrder by FAX

Summary

Please Note: Reports are sold based on the user licenses indicated. The reports will be accessible in Flash format via an online reading room on the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order,the client will receive an email with information on accessing their purchase.

Driven by demographic trends, such as an increasing aged population, the global ophthalmic pharmaceutical market is set to become a serious growth area experiencing a compound annual growth rate of 11.11 per cent to 2012. This report explains just how this market will experience growth over the medium term future. Also do you know what the drivers and restraints of the market are? This report not only reveals these, but also details what strategies can be used to maximize profits from the drivers and restraints.

The Ophthalmic pharmaceutical market is divided into six major diseases.

These are:

  • Glaucoma
  • Age-related macular degeneration
  • Dry eye syndrome
  • Ocular allergy
  • Ocular inflammation
  • Ocular infection

In this report each one of these disease areas is examined in terms of market growth and revenue, current and future drug treatments, market analysis, and major companies involved.

According to the findings of this new 175+ page report, visiongain reveals that Glaucoma therapies are set to dominate the market over the forecast period (2007-2012), accounting for over 40 per cent of market revenues by 2012. Pfizer's product Xalatan, used to lower intraocular pressure to treat glaucoma, will generate blockbuster revenues in 2007, and continue to dominate the entire ophthalmic pharmaceutical market. However are there any others which can compete with this for market share or beat its dominance? This report answers that question, with an analysis of other players in the market.

Do you know what the market values of these major therapeutic areas of the ophthalmic world market are?

The report provides in-depth market analysis upon these areas, and extensively identifies both prescription and OTC ophthalmic drugs by disease and product type. The study also assess' the challenges faced by ophthalmic companies, and what exciting market opportunities exist in this up- and-coming therapeutic area.

Why You Must Buy This Report:

This report features over 50 tables, 20 graphs and charts, news, insights, the latest developments and an in depth survey of the opthalmic market with up-to-date analysis. This report is a vital addition to gaining an understanding of this highly profitable market sector and will give your company 'the edge' on your competitors. You can not afford to be without this latest report from visiongain.

With an increasing aged population and unmet medical needs this market is set to grow rapidly, but by how much? This report will tell you. Brought together in one easy to read, easily digested format, this report will keep you fully informed and up-to-date on the global ophthalmic pharmaceutical market.

Key questions that this report answers:

  • Which current or future therapies will drive the ophthalmic market?
  • The key companies involved in the market and their analysis?
  • What R&D opportunities exist for 'new comers'?
  • What are the current and future blockbusters within the ophthalmic industry?

Unique benefits to you when you order this report:

  • Immediate access through our exclusive Reading Room
  • You can access your report whichever country you are in without using harddrive space
  • Primary research throughout. You will not find this information anywhere else
  • Report stored in your reading room for ever
  • Full searchable report when you buy the company or corporate editions
  • Copies can be printed off for offline reading
  • Packed with charts, analysis, figures, graphs and tables

Content

  • Chapter 1: Executive Summary
    • 1.1 The World Ophthalmics Market 2007
    • 1.2 Introduction to Ophthalmics, 2007
    • 1.3 Summary of Ophthalmics, 2007
      • 1.3.1 The Top Three Selling Ophthalmic Drugs, 2006
      • 1.3.2 The Top Three Ophthalmic Drugs Revenue Forecasts ($m), 2007-2012
  • Chapter 2: The World Ophthalmic Pharmaceutical Market
    • 2.1 Ophthalmic Industry Segmentation
      • 2.1.1 Defining Key Ophthalmic Diseases
      • 2.1.2 Defining Surgical Equipment Area
      • 2.1.3 Defining Vision Care
    • 2.2 The Worldwide Ophthalmic Pharmaceutical Market, 2007-2012
    • 2.3 An Overview of the Eye
      • 2.3.1 Anatomy of the Human Eye
      • 2.3.2 The Vision Process
    • 2.4 The Leading Ophthalmic Disease Profiles:Description and Prevalence
      • 2.4.1 The Four Stages of Diabetic Retinopathy
      • 2.4.2 Age Related Macular Degeneration (AMD)
      • 2.4.3 Cataract: Surgery Offers Best Treatment
      • 2.4.4 Glaucoma
      • 2.4.5 Prevalence of Major Ophthalmic Diseases
    • 2.5 The Top 10 Major Selling Ophthalmic Drugs and Their Manufacturers, 2005
    • 2.6 Key Companies in the Ophthalmic Pharmaceutical Market
    • 2.7 Drivers for the Ophthalmic Market
      • 2.7.1 Ageing Population Leads to Increased Vision Loss
      • 2.7.2 New Drug Delivery Techniques
      • 2.7.3 Back-of-the-Eye Therapy: Future Looks Promising
    • 2.8 Restraints for the Ophthalmic Market
      • 2.8.1 The Lack of Involvement of Key Pharma Companies
    • 2.9 Strategic Options in the Ophthalmic Industry
    • 2.10 The Economic Cost of Eye Diseases
    • 2.11 Market Opportunities to Target
  • Chapter 3. The Worldwide Glaucoma Pharmaceuticals Market
    • 3.1 An Introduction to Glaucoma: the Leading Cause of Blindness in the Ophthalmic Market
      • 3.1.1 Normal Fluid Drainage in the Eye
      • 3.1.2 The Main Causes of Glaucoma
      • 3.1.3 Risk Factors for Glaucoma
    • 3.2 Primary Open Angle Glaucoma: The Most Common Form
    • 3.3 Closed Angle Glaucoma - Less Common
    • 3.4 Secondary Glaucoma: Mild or Severe?
    • 3.5 Normal Tension Glaucoma (NTG) - Optic Nerve Damage
    • 3.6 Pigmentary Glaucoma Causes Increase in Eye Pressure
    • 3.7 Current Glaucoma Drug Treatments Available
      • 3.7.1 Drug Classes That Increase Aqueous Humour Outflow
      • 3.7.2 Drugs Classes That Increase Aqueous Humour Production
      • 3.7.3 Aqueous Humour Volume Reduction Via Hyperosmolars
    • 3.8 Beta Blockers: The Primary Treatment for Glaucoma or Not?
      • 3.8.1 Analysis of Beta Blocker Drugs
    • 3.9 Prostaglandin Analogues the Leading Glaucoma Treatment
      • 3.9.1 Glaucoma Dominance Due to the Success of Xalatan
      • 3.9.2 Price Could Play a Major Role in Prostaglandins Success
    • 3.10 Docosanoids as Novel Glaucoma Therapies
    • 3.11 Miotics - Many Drugs Available
    • 3.12 Carbonic Anhydrase Inhibitors - Limited Choice of Drugs
      • 3.12.1 Trusopt
      • 3.12.2 Azopt - The Latest CAI
    • 3.13 Alpha Agonists - Limited Availability
    • 3.14 Hyperosmolars - Uncommon Glaucoma Treatment
    • 3.15 Combination Therapies - Future Looks Promising
    • 3.16 Glaucoma Drugs Preferred Than Surgery
    • 3.17 Glaucoma Worldwide Market: A Dormant Giant
    • 3.18 Prostaglandins Treatment Lead the Glaucoma Market
    • 3.19 Key Drivers in the Glaucoma Market
    • 3.20 Some Restraints in the Glaucoma Market
    • 3.21 The Top 10 Selling Glaucoma Drugs in 2005
    • 3.22 Pfizer's Blockbuster dominates the Glaucoma Market
    • 3.23 The World Market Share of Top 10 Selling Glaucoma Drugs, 2005
    • 3.24 The Market Share of the Top 10 Selling Glaucoma Drugs by Company
    • 3.25 Company Market Share (%) of the World Top 10 Selling Glaucoma Drugs, 2005
    • 3.26 Glaucoma Pipeline Products, 2007
    • 3.27 Glaucoma Market Opportunities: Door Wide Open
  • Chapter 4: Age Related Macular Degeneration (AMD) Pharmaceuticals Market
    • 4.1 An Introduction to Wet and Dry AMD: The Cause of Vision Loss in the Senior Population
    • 4.2 Risk Factors Associated with AMD
    • 4.3 AMD Prevalence
      • 4.3.1 Wet AMD Prevalence
      • 4.3.2 Dry AMD Prevalence
    • 4.4 Dry AMD: No Proven Treatments, Yet
    • 4.5 Drug Treatments for Wet AMD
    • 4.6 Current AMD Drug Therapies
    • 4.7 Lucentis v Avastin - cost and dose but no clinical trial
    • 4.8 Future Treatments for AMD
    • 4.9 Drug Therapies in the AMD Market Provides Commercial Targets
    • 4.10 Market Drivers in the AMD Market
    • 4.11 Market Restraints in the AMD Market
    • 4.12 Lucentis Revenues: An eye opener
    • 4.13 The Worldwide AMD Drug Market
    • 4.14 Pipeline Products in the AMD Market
    • 4.15 AMD Market Opportunities: Many Targets to Hit
  • Chapter 5: Ocular Allergies Pharmaceuticals Market
    • 5.1 An Introduction to Ocular Allergies
    • 5.2 Seasonal & Perennial Allergic Conjunctivitis - Most Common Types
      • 5.2.1 Seasonal Allergic Conjunctivitis - Manifestation of Hayfever
      • 5.2.2 Perennial Allergic Conjunctivitis: Persistant
    • 5.3 Giant Papillary Conjunctivitis - Inflammatory Disorder
    • 5.4 Vernal Keratoconjunctivitis - the Recurring Disease
    • 5.5 Atopic Keratoconjunctivitis - Year Round Disease
    • 5.6 An Overview of Ocular Allergy Drug Treatments
    • 5.7 Antihistamines (H1-Receptor Antagonists)
    • 5.8 Mast Cell Stabilisers Have Slow Onset of Action
    • 5.9 Topical NSAIDs Have High Adverse Effect Incidence
    • 5.10 Corticosteroids - Long-term Use Dangerous
    • 5.11 Long Lasting Dual/Multiple-Action Agents
    • 5.12 The Deciding Factor Between Systemic and Topical Medications
    • 5.13 Alcon's Patanol: Dominates the Ocular Allergy Market
    • 5.14 Market Drivers in the Ocular Allergy Market
    • 5.15 Market Restraints in the Ocular Allergy Market
    • 5.16 The Ocular Allergy Worldwide Market: Alcon's Patanol Dominates
    • 5.17 Ocular Allergy Pipeline Products, 2007
    • 5.18 Ocular Allergy Market Opportunities
    • 5.19 The Future for Ocular Allergies
  • Chapter 6: Dry Eye Syndrome Pharmaceuticals Market
    • 6.1 Introduction to Dry Eye Syndrome - Tear Film Disorder
    • 6.2 The Causes of Dry Eye Syndrome is Associated With Aging
    • 6.3 High-Risk Populations for Dry Eye Syndrome
    • 6.4 An Overview of DES Drug Treatments
    • 6.5 Drug Treatment of Dry Eye - Artificial Tears Remain 1st Choice
    • 6.6 Low Viscosity Artificial Tears
    • 6.7 Moderate Viscosity Artificial Tears
    • 6.8 High Viscosity Artificial Tears
    • 6.9 Gel Formulations - The Novel System
    • 6.10 Lubricating Ointments - Uncommonly Used
    • 6.11 Restasis: Only Prescription Eye Drop
    • 6.12 Mechanism of Action of Restasis
    • 6.13 Allergy or Dryness: The Argument Continues
    • 6.14 DES Market Drivers
    • 6.15 DES Market Restraints
    • 6.16 The Dry Eye Worldwide Drug Market: Restasis Leads the Market
    • 6.17 Pipeline Products in the Dry Eye Market
    • 6.18 Secretagogues: New Treatment Perhaps?
    • 6.19 DES Market Opportunities
  • Chapter 7: Ocular Infections Pharmaceuticals Market
    • 7.1 An Introduction to Ocular Infections
    • 7.2 Hordeolum - Most Common Eyelid Lesions in the US
      • 7.2.1 External Hordeolum - Small Yellowish Spot
      • 7.2.2 Internal Hordeolum - Very Severe
    • 7.3 Blepharitis - Inflammation of the Eyelids
    • 7.4 Introduction to Conjunctivitis - Pink Eye
    • 7.5 Bacterial Conjunctivitis - The Self-Limited illness
    • 7.6 Viral Conjunctivitis - Affects All Ages
    • 7.7 Epidemic Keratoconjunctivitis - Highly Contagious
    • 7.8 Pharyngoconjunctival Fever - Child Fever
    • 7.9 Keratitis - The Corneal Infection
    • 7.10 Herpes Simplex Keratitis - Common Human Infection
    • 7.11 Bacterial Keratitis - Sight-Threatening Disease
    • 7.12 Fungal Keratitis - Remains a Challenge
    • 7.13 Acanthamoeba Keratitis - Parasite Invader
    • 7.14 Ocular Infection Drug Treatments
    • 7.15 Topical Antibiotics: Fluroquinolones
      • 7.15.1 4th Generation Fluroquinolones: Potent and Beneficial Agents
      • 7.15.2 Problems Associated With Fluroquinolones
      • 7.15.3 Aminoglycosides: Alcon's Tobrex Performs Well
      • 7.15.4 Erythromycin - Protein Inhibitor
      • 7.15.5 Bacitracin - The Drug of Choice
      • 7.15.6 Polymyxin B Combinations - Potent Killer
    • 7.16 Systemic Antibacterials
    • 7.17 Antivirals - Choice Limited
    • 7.18 Antifungals - Wide Range Available
    • 7.19 Ocular Infection Market Drivers
    • 7.20 Ocular Infection Market Restraints
    • 7.21 The Worldwide Ocular Infection Drug Market:Vigamox Dominates
    • 7.22 Ocular Infection Pipeline Products, 2007
    • 7.23 Ocular Infection Market Opportunities
  • Chapter 8: Ocular Inflammatory Pharmaceuticals Market
    • 8.1 Ocular Inflammatory Disorders: An Overview
    • 8.2 Chalazion - Painless But Deadly
    • 8.3 Uvetitis - Common Cause of Vision Loss in the Young
      • 8.3.1 Anterior Uveitis - Most Symptomatic
      • 8.3.2 Intermediate Uveitis - Associated with Decreased Vision
      • 8.3.3 Posterior Uveitis - Similar to Intermediate Uveitis
    • 8.4 Topical Corticosteroids Remains the Primary Ocular Anti-Inflammatory Therapy
    • 8.5 Topical Corticosteroids Available on the 2007 Market
      • 8.5.1 Topical Steroids with Maximum Efficacy
      • 8.5.2 Topical Moderate-Strength Steroids
    • 8.6 Corticosteroid Ointment Treatments
    • 8.7 Oral Corticosteroids - Not Commonly Used
    • 8.8 Topical NSAIDS - Stings on Treatment
    • 8.9 COX-2 Inhibitors - Only One Remains
    • 8.10 Ocular Inflammation Market Drivers
    • 8.11 Ocular Inflammation Market Restraints
    • 8.12 The Worldwide Ocular Inflammation Drug Market, 2007-2012
    • 8.13 Ocular Inflammatory Pipeline Products, 2007
    • 8.14 Ocular Inflammatory Market Opportunities
  • Chapter 9: Conclusion
    • 9.1 The Ophthalmic Pharmaceutical Market is Headed for High Consistent Financial Growth
  • List of Tables
    • Table 1.1 Total Worldwide Pharmaceutical Ophthalmic Market Forecast ($bn), 2007 2012
    • Table 1.2 Top Three Selling Ophthalmic Drugs in 2006
    • Table 1.3 Xalatan Revenue Forecast ($m), 2007-2012
    • Table 1.4 Cosopt Revenue Forecast ($m), 2007-2012
    • Table 1.5 Lucentis Revenue Forecast ($m), 2007-2012
    • Table 2.1 Total Worldwide Pharmaceutical Ophthalmic Market Forecast ($bn), 2007-2012
    • Table 2.2 Worldwide Pharmaceutical Ophthalmic Market Forecast by Disease ($bn), 2007-2012
    • Table 2.3 Ophthalmic Disease Area Market Share (%), 2006, 2009 and 2012
    • Table 2.4 Prevalence of Cataract, AMD and Open Angle Glaucoma Among Adults 40 Years and Older in the US, 2004
    • Table 2.5 Prevalence of Diabetic Retinopathy Among Adults in the US, 2004
    • Table 2.6 Estimated Prevalence of Myopia and Hyperopia Among Adults in the US, 2006
    • Table 2.7 Revenues ($m) of the Top 10 Selling Ophthalmic Drugs, 2005
    • Table 2.8 Top 10 Selling Ophthalmic Drugs by Market Share (%), 2005
    • Table 2.9 Advantages and Disadvantages of Ophthalmic Drug Delivery Routes
    • Table 3.1 Current Beta Blockers used to treat Glaucoma, 2007
    • Table 3.2 Current Prostaglandins used to treat Glaucoma, 2007
    • Table 3.3 Current Miotics used to treat Glaucoma, 2007
    • Table 3.4 Current Carbonic Anhydrase Inhibitors used to treat Glaucoma, 2007
    • Table 3.5 Current Combination therapies used to treat Glaucoma, 2007
    • Table 3.6 Summary of Glaucoma drugs by Company, 2007
    • Table 3.7 Total World Glaucoma Drug by Treatment Class Market Forecast ($bn), 2007-2012
    • Table 3.8 Total World Glaucoma Drug by Treatment Class Market Share Forecast (%), 2007-2012
    • Table 3.9 Top 10 Selling ($m) Glaucoma Drugs by Company, 2005
    • Table 3.10 Market Share (%) of Top 10 Selling Glaucoma drugs, 2005
    • Table 3.11 Market Share (%) of Top 10 Selling Glaucoma Drugs by Company, 2005
    • Table 3.12 Glaucoma Pipeline Products, 2007
    • Table 4.1 The prevalence of wet AMD worldwide in 2006 and 2025
    • Table 4.2 The prevalence of dry AMD worldwide in 2006 and 2025
    • Table 4.3 Current Drug Treatments for Wet AMD, 2007
    • Table 4.4 Lucentis Revenue Forecast ($bn), 2007-2012
    • Table 4.5 Total Worldwide AMD Drug Market Forecast ($bn) 2007-2012
    • Table 4.6 Pipeline AMD Products, 2007
    • Table 5.1 Antihistamine Products
    • Table 5.2 Mast Cell Stabiliser Products
    • Table 5.3 Topical Corticosteroid Top Products
    • Table 5.4 Dual Action Products
    • Table 5.5 Summary of Products Used to Treat Ocular Allergies, 2007
    • Table 5.6 Total Worldwide Ocular Allergy Drug Market Forecast ($bn), 2007-2012
    • Table 5.7 Ocular Allergy Pipeline Products, 2007
    • Table 6.1 Low Viscosity Artificial Tear Products Available, 2007
    • Table 6.2 Moderate Viscosity Artificial Tear Products Available, 2007
    • Table 6.3 High Viscosity Artificial Tear Products Available, 2007
    • Table 6.4 Gel Formation Products Available, 2007
    • Table 6.5 Lubricating Ointment Products Available, 2007
    • Table 6.6 Summary of Available Drug Therapies Used to Treat Dry Eye Syndrome, 2007
    • Table 6.7 Total World Dry Eye Drug Market Revenue Forecast ($bn), 2007-2012
    • Table 7.1 List of Ocular Infections
    • Table 7.2 Systemic Antiviral Drug Products Available
    • Table 7.3 Antifungal Ophthalmic Drug Products
    • Table 7.4 Summary of Drug Products Available to Treat Ocular Infections
    • Table 7.5 Total World Ocular Infection Drug Market Revenue Forecast ($bn), 2007-2012
    • Table 7.6 Ocular Infection Product Pipeline, 2007
    • Table 8.1 Topical Corticosteroid Drugs Available
    • Table 8.2 Summary of Ocular Inflammatory Products
    • Table 8.3 Total World Ocular Inflammation Drug Market Revenue Forecast ($bn), 2007-2012
    • Table 8.4 Ocular Inflammation Pipeline Products, 2007
  • List of Graphs
    • Graph 1.1 Total World Ophthalmic Pharmaceutical Market Forecast ($bn), 2007-2012 Graph 2.1 Total World Ophthalmic Pharmaceutical Market Forecast ($bn), 2007-2012 Graph 2.2 Total World Ophthalmic Pharmaceutical Annual Growth Rate (%), 2007-2012
    • Graph 3.1 Glaucoma World Market Forecast ($bn), 2007-2012
    • Graph 3.2 Glaucoma World Market Growth (%), 2007-2012
    • Graph 4.1 The Prevalence of Three Major Causes of Blindness Among Adults 40 Years and Older in the US
    • Graph 4.2 Lucentis Revenue Forecast ($bn), 2007-2012
    • Graph 4.3 Lucentis Growth Forecast (%), 2007-2012
    • Graph 4.4 Total World AMD Market Revenue Forecast ($bn), 2007-2012
    • Graph 4.5 Total World AMD Market Growth Forecast (%), 2007-2012
    • Graph 5.1 Total World Ocular Allergy Market Revenue Forecast ($bn), 2007-2012
    • Graph 5.2 Total World Ocular Allergy Market Growth Forecast (%), 2007-2012
    • Graph 6.1 Total World Dry Eye Market Revenue Forecast ($bn), 2007-2012
    • Graph 6.2 Total World Dry Eye Market Growth Forecast (%), 2007-2012
    • Graph 7.1 Total World Ocular Infection Market Revenue Forecast ($bn), 2007-2012
    • Graph 7.2 Total World Ocular Infection Market Growth Forecast (%), 2007-2012
    • Graph 8.1 Total World Ocular Inflammation Market Revenue Forecast ($bn), 2007-2012
    • Graph 8.2 Total World Ocular Inflammation Market Growth Forecast (%), 2007-2012
  • List of Charts
    • Chart 2.1 Ophthalmic Disease Area Market Share (%), 2006
    • Chart 2.2 Ophthalmic Disease Area Market Share (%),2009
    • Chart 2.3 Ophthalmic Disease Area Market Share (%), 2012
    • Chart 2.4 Top 10 Selling Ophthalmic Drug Companies Market Share (%), 2005
    • Chart 3.1 Glaucoma Drug by Class Market Share (%), 2006
    • Chart 3.2 Glaucoma Drug by Class Market Share (%), 2009
    • Chart 3.3 Glaucoma Drug by Class Market Share (%), 2012
    • Chart 3.4 Market Share (%) of Top 10 Selling Glaucoma Drugs, 2005
    • Chart 3.5 Company Market Share (%) of Top 10 Selling Glaucoma Drugs, 2005
    • Chart 6.1 Causes of Dry Eye Picture 2.1 Anatomy of the Human Eye
  • Companies Mentioned
    • Acadia
    • Acuity Pharmaceuticals
    • Advanced Vision Research
    • Akorn
    • Alcon
    • Alimera Sciences
    • Allergan
    • Alza
    • Asah Glass
    • ASTA
    • AstraZeneca
    • Aventis
    • Banyu Pharmaceuticals
    • Barr
    • Bausch & Lomb
    • Baxter
    • Bio-Logic Aqua Technology
    • BMS
    • Celegene
    • Celltech
    • Chauvin
    • CIBA Vision
    • Daiichi Nippon
    • Dista
    • Eyetech Pharmaceuticals
    • Fujisawa
    • Genera
    • Genetech
    • Genvec
    • Gilead Sciences
    • Goldshield
    • GSK
    • Inflazyme Pharmaceuticals
    • Insite
    • Inspire Pharmaceuticals
    • Isis Pharmaceuticals
    • ISTA
    • Ixis
    • Janseen Pharmaceuticals
    • Karo Bio SIFI
    • Medimmune
    • Merck
    • Miravant Medical Technology
    • Monarch
    • Norvartis
    • Novagali
    • Oculex
    • OcuSoft
    • Orgaeon
    • Orhto-McNeil Pharmaceuticals
    • Othera
    • Oxigene
    • Pfizer
    • Pharmadix
    • Pliva Pharmaceuticals
    • QLT
    • Restan
    • Roche
    • Sankyo
    • Santen
    • Scherag
    • Schering-Plough
    • Senju
    • Sucampo Pharmaceuticals
    • Vista Scientific
    • Wyeth

back to top

About this Product
Delivery Details

REPORT:Despatched within 3 to 5 working days.

Ask a question about this product?

Need help finding the right product?

Related Products
Recently Viewed Products
Global Ophthalmic Market Analysis & Forecasts to 2012

Industry Events

2nd Annual Global Generic Medicines Summit

27 Feb 08 to 28 Feb 08
London, UK
view summary >>

Healthcare New Media PR and Marketing Conference

15 Jun 09 to 17 Jun 09
Phoenix, US
view summary >>

Intelligent comment on RBlog
#

Pharma & Healthcare

Customer Services

How To Buy
Formats & Delivery
Terms & Conditions
Account Options
Login/Register

call +44 (0) 20 7060 7474
or email us

Resources

Why Report Buyer?
Advertising/Affiliates
View Our Publishers
News
About Us
Market Publishers
Meet Us
Jobs
Contact Us
Categories and Subcategories

Post it

Del.icio.us
StumbleUpon
Reddit

logo: AddThis